IL1 receptor antagonist controls transcriptional signature of inflammation in patients with metastatic breast cancer
© 2018 American Association for Cancer Research. Inflammation affects tumor immune surveillance and resistance to therapy. Here, we show that production of IL1b in primary breast cancer tumors is linked with advanced disease and originates from tumor-infiltrating CD11cþmyeloid cells. IL1b production is triggered by cancer cell membrane–derived TGFb. Neutralizing TGFb or IL1 receptor prevents breast cancer progression in humanized mouse model. Patients with metastatic HER2 breast cancer display a transcriptional signature of inflammation in the blood leukocytes, which is attenuated after IL1 blockade. When present in primary breast cancer tumors, this signature discriminates patients with poor clinical outcomes in two independent public datasets (TCGA and METABRIC). Significance: IL1b orchestrates tumor-promoting inflammation in breast cancer and can be targeted in patients using an IL1 receptor antagonist.
Digital Object Identifier (DOI)
Additional Document Info
has global citation frequency